Orthofix Intl Nv (OFIX) 44.33 $OFIX
Orthofix to Participate in Jefferies 2016 Healthcare Conference
BusinessWire - Thu May 26, 4:03PM CDT
Orthofix International N.V. (NASDAQ:OFIX), a diversified, global medical device company, today announced that it will participate in the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 in New York City. President and Chief Executive Officer Brad Mason will represent the Company in a presentation scheduled for 10:30 a.m. ET.
OFIX: 44.33 (-0.42)
Orthofix Announces 510(k) Clearance and US Limited Market Launch of FORZA PTC Interbody Spacer System
BusinessWire - Mon May 16, 7:00AM CDT
Orthofix International N.V. (NASDAQ:OFIX), a diversified, global medical device company, today announced the 510(k) clearance and U.S. limited market launch of the FORZA(R) PTC(TM) (Peek Titanium Composite) Spacer System. Designed and manufactured using a proprietary method, FORZA PTC spacers combine PEEK and 3D printed titanium end plates into a single porous interbody solution for lumbar spine fusion procedures. FORZA PTC interbody spacers are designed to restore normal disc height in patients suffering from degenerative disc disease.
OFIX: 44.33 (-0.42)
IDEXX Laboratories (IDXX) Tops Q1 Earnings; Lifts '16 View
Zacks Equity Research - Zacks Investment Research - Mon May 02, 7:42AM CDT
IDEXX (IDXX) started off 2016 on a strong note; with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 22.66 (-0.10), BAX: 44.94 (-0.07), IDXX: 90.04 (+0.38), OFIX: 44.33 (-0.42)
Align Technology (ALGN) Beats on Q1 Earnings & Revenues
Zacks Equity Research - Zacks Investment Research - Mon May 02, 7:37AM CDT
Align Technology (ALGN) kick-started 2016 on a promising note, with its first-quarter results squarely beating the Zacks Consensus Estimate
BSX: 22.66 (-0.10), ALGN: 80.42 (+1.08), BAX: 44.94 (-0.07), OFIX: 44.33 (-0.42)
GNC Holdings (GNC) Q1 Earnings Lag, Cash Position Strong
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 12:39PM CDT
2016 started off on a disappointing note for GNC Holdings (GNC), with its first-quarter results squarely missing the Zacks Consensus Estimate.
BSX: 22.66 (-0.10), BAX: 44.94 (-0.07), GNC: 25.40 (+0.65), OFIX: 44.33 (-0.42)
Cepheid (CPHD) Q1 Loss Narrower than Expected, Sales Top
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 10:31AM CDT
Cepheid (CPHD) started 2016 on a compelling note with its first-quarter results exceeding the Zacks Consensus Estimate on both the top and bottom-line front.
BSX: 22.66 (-0.10), BAX: 44.94 (-0.07), CPHD: 29.50 (+0.14), OFIX: 44.33 (-0.42)
Orthofix posts 1Q profit
Automated Insights - Thu Apr 28, 4:45PM CDT
WILLEMSTAD, Netherlands Antilles (AP) _ Orthofix International NV (OFIX) on Thursday reported first-quarter net income of $3.9 million, after reporting a loss in the same period a year earlier.
OFIX: 44.33 (-0.42)
Orthofix International Reports First Quarter 2016 Financial Results
BusinessWire - Thu Apr 28, 3:01PM CDT
--Net sales of $98.7 million; an increase of 11.8% over prior year on a constant currency basis
OFIX: 44.33 (-0.42)
Qiagen (QGEN) Q1 Earnings Meet, Revenues Top; View Intact
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:26PM CDT
Qiagen (QGEN) started 2016 on a promising note with a satisfactory first quarter.
BSX: 22.66 (-0.10), QGEN: 21.75 (+0.36), NUVA: 57.79 (+0.06), OFIX: 44.33 (-0.42)
Mead Johnson (MJN) Tops Q1 Earnings & Sales, View Intact
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:03PM CDT
Mead Johnson (MJN) embarked on a promising journey this year, posting square beats in the first quarter of 2016.
BSX: 22.66 (-0.10), MJN: 87.45 (-0.96), NUVA: 57.79 (+0.06), OFIX: 44.33 (-0.42)
5 Low-Beta Stocks to Brave Market Volatility
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 11:52AM CDT
Risk-averse investors are always on the lookout for stocks that are less exposed to the market.
FN: 36.37 (-0.86), NEM: 35.72 (+0.89), ULTA: 238.23 (-2.24), WIN: 9.07 (-0.28), OFIX: 44.33 (-0.42)
Edwards Lifesciences (EW) Q1 Earnings Top; '16 View Up
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 9:26AM CDT
Edwards Lifesciences (EW) wrapped up the first quarter on a positive note, with results outshining estimates on both the top and bottom-line front.
BSX: 22.66 (-0.10), CSII: 17.54 (-0.02), EW: 98.04 (-0.53), OFIX: 44.33 (-0.42)
ResMed (RMD) Q3 Earnings Miss, Revenues Meet Estimates
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 8:04AM CDT
ResMed 9RMD) ended third-quarter fiscal 2016 on a modest note. Nevertheless, ResMed posted positive year-over-year growth as far as its segmental and geographical results are concerned.
BSX: 22.66 (-0.10), CSII: 17.54 (-0.02), RMD: 62.33 (+0.55), OFIX: 44.33 (-0.42)
Orthofix International Schedules First Quarter 2016 Earnings Release and Conference Call for April 28, 2016
BusinessWire - Thu Apr 21, 3:32PM CDT
Orthofix International N.V. (NASDAQ:OFIX) (the "Company"
a diversified, global medical device company, today announced that it plans to release first quarter 2016 financial results after market close on Thursday, April 28, 2016. Brad Mason, Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company's results at 4:30 p.m. EDT the same day.
OFIX: 44.33 (-0.42)
Quest Diagnostics: Expanded Use of HCV Test Services
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 12:10PM CDT
We believe the introduction of these new test services reflects Quest Diagnostics' (DGX) progress in the emerging precision medicine space.
BAX: 44.94 (-0.07), DGX: 79.59 (+1.72), LMAT: 14.69 (+0.15), OFIX: 44.33 (-0.42)
GNC Holdings: Retail a Bright Spot, Cash Balance Strong
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 12:00PM CDT
During 2015, GNC Holdings (GNC) generated operating cash flow of over $50.7 million, resulting in a 31.6% rise in free cash flow.
BAX: 44.94 (-0.07), GNC: 25.40 (+0.65), LMAT: 14.69 (+0.15), OFIX: 44.33 (-0.42)
Edwards Lifesciences' Solid Pipeline, Product Suite Impress
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 1:25PM CDT
Edwards Lifesciences (EW) ended 2015 on an outstanding note, with its fourth quarter numbers squarely beating the Zacks Consensus Estimate.
BAX: 44.94 (-0.07), LMAT: 14.69 (+0.15), EW: 98.04 (-0.53), OFIX: 44.33 (-0.42)
PAREXEL (PRXL): A Strong Buy on Solid Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 11:10AM CDT
On Apr 12, Zacks Investment Research raised PAREXEL International Corporation (PRXL) to a Zacks Rank #1 (Strong Buy).
PRXL: 59.45 (+0.07), LMAT: 14.69 (+0.15), PRAH: 42.91 (+0.43), OFIX: 44.33 (-0.42)
Phibro Animal Declines as FDA Moves to Revoke Mecadox
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 12:50PM CDT
A recent reexamination by the FDA has led the authority to question Phibro Animal Health Corporation's (PAHC) Mecadox drug's safety.
PAHC: 20.07 (+0.45), BAX: 44.94 (-0.07), LMAT: 14.69 (+0.15), OFIX: 44.33 (-0.42)
ResMed: Strong Cash Balance, Product Portfolio Drive Growth
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 1:50PM CDT
ResMed (RMD) currently has a strong cash balance, as evident from $269.5 million in cash flow from operations generated during the fiscal 2016 second quarter
BAX: 44.94 (-0.07), LMAT: 14.69 (+0.15), RMD: 62.33 (+0.55), OFIX: 44.33 (-0.42)
Orthofix to Participate in Jefferies 2016 Healthcare Conference
BusinessWire - Thu May 26, 4:03PM CDT
Orthofix International N.V. (NASDAQ:OFIX), a diversified, global medical device company, today announced that it will participate in the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 in New York City. President and Chief Executive Officer Brad Mason will represent the Company in a presentation scheduled for 10:30 a.m. ET.
OFIX: 44.33 (-0.42)
Orthofix Announces 510(k) Clearance and US Limited Market Launch of FORZA PTC Interbody Spacer System
BusinessWire - Mon May 16, 7:00AM CDT
Orthofix International N.V. (NASDAQ:OFIX), a diversified, global medical device company, today announced the 510(k) clearance and U.S. limited market launch of the FORZA(R) PTC(TM) (Peek Titanium Composite) Spacer System. Designed and manufactured using a proprietary method, FORZA PTC spacers combine PEEK and 3D printed titanium end plates into a single porous interbody solution for lumbar spine fusion procedures. FORZA PTC interbody spacers are designed to restore normal disc height in patients suffering from degenerative disc disease.
OFIX: 44.33 (-0.42)
IDEXX Laboratories (IDXX) Tops Q1 Earnings; Lifts '16 View
Zacks Equity Research - Zacks Investment Research - Mon May 02, 7:42AM CDT
IDEXX (IDXX) started off 2016 on a strong note; with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 22.66 (-0.10), BAX: 44.94 (-0.07), IDXX: 90.04 (+0.38), OFIX: 44.33 (-0.42)
Align Technology (ALGN) Beats on Q1 Earnings & Revenues
Zacks Equity Research - Zacks Investment Research - Mon May 02, 7:37AM CDT
Align Technology (ALGN) kick-started 2016 on a promising note, with its first-quarter results squarely beating the Zacks Consensus Estimate
BSX: 22.66 (-0.10), ALGN: 80.42 (+1.08), BAX: 44.94 (-0.07), OFIX: 44.33 (-0.42)
GNC Holdings (GNC) Q1 Earnings Lag, Cash Position Strong
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 12:39PM CDT
2016 started off on a disappointing note for GNC Holdings (GNC), with its first-quarter results squarely missing the Zacks Consensus Estimate.
BSX: 22.66 (-0.10), BAX: 44.94 (-0.07), GNC: 25.40 (+0.65), OFIX: 44.33 (-0.42)
Cepheid (CPHD) Q1 Loss Narrower than Expected, Sales Top
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 10:31AM CDT
Cepheid (CPHD) started 2016 on a compelling note with its first-quarter results exceeding the Zacks Consensus Estimate on both the top and bottom-line front.
BSX: 22.66 (-0.10), BAX: 44.94 (-0.07), CPHD: 29.50 (+0.14), OFIX: 44.33 (-0.42)
Orthofix posts 1Q profit
Automated Insights - Thu Apr 28, 4:45PM CDT
WILLEMSTAD, Netherlands Antilles (AP) _ Orthofix International NV (OFIX) on Thursday reported first-quarter net income of $3.9 million, after reporting a loss in the same period a year earlier.
OFIX: 44.33 (-0.42)
Orthofix International Reports First Quarter 2016 Financial Results
BusinessWire - Thu Apr 28, 3:01PM CDT
--Net sales of $98.7 million; an increase of 11.8% over prior year on a constant currency basis
OFIX: 44.33 (-0.42)
Qiagen (QGEN) Q1 Earnings Meet, Revenues Top; View Intact
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:26PM CDT
Qiagen (QGEN) started 2016 on a promising note with a satisfactory first quarter.
BSX: 22.66 (-0.10), QGEN: 21.75 (+0.36), NUVA: 57.79 (+0.06), OFIX: 44.33 (-0.42)
Mead Johnson (MJN) Tops Q1 Earnings & Sales, View Intact
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:03PM CDT
Mead Johnson (MJN) embarked on a promising journey this year, posting square beats in the first quarter of 2016.
BSX: 22.66 (-0.10), MJN: 87.45 (-0.96), NUVA: 57.79 (+0.06), OFIX: 44.33 (-0.42)
5 Low-Beta Stocks to Brave Market Volatility
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 11:52AM CDT
Risk-averse investors are always on the lookout for stocks that are less exposed to the market.
FN: 36.37 (-0.86), NEM: 35.72 (+0.89), ULTA: 238.23 (-2.24), WIN: 9.07 (-0.28), OFIX: 44.33 (-0.42)
Edwards Lifesciences (EW) Q1 Earnings Top; '16 View Up
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 9:26AM CDT
Edwards Lifesciences (EW) wrapped up the first quarter on a positive note, with results outshining estimates on both the top and bottom-line front.
BSX: 22.66 (-0.10), CSII: 17.54 (-0.02), EW: 98.04 (-0.53), OFIX: 44.33 (-0.42)
ResMed (RMD) Q3 Earnings Miss, Revenues Meet Estimates
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 8:04AM CDT
ResMed 9RMD) ended third-quarter fiscal 2016 on a modest note. Nevertheless, ResMed posted positive year-over-year growth as far as its segmental and geographical results are concerned.
BSX: 22.66 (-0.10), CSII: 17.54 (-0.02), RMD: 62.33 (+0.55), OFIX: 44.33 (-0.42)
Orthofix International Schedules First Quarter 2016 Earnings Release and Conference Call for April 28, 2016
BusinessWire - Thu Apr 21, 3:32PM CDT
Orthofix International N.V. (NASDAQ:OFIX) (the "Company"
a diversified, global medical device company, today announced that it plans to release first quarter 2016 financial results after market close on Thursday, April 28, 2016. Brad Mason, Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company's results at 4:30 p.m. EDT the same day. OFIX: 44.33 (-0.42)
Quest Diagnostics: Expanded Use of HCV Test Services
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 12:10PM CDT
We believe the introduction of these new test services reflects Quest Diagnostics' (DGX) progress in the emerging precision medicine space.
BAX: 44.94 (-0.07), DGX: 79.59 (+1.72), LMAT: 14.69 (+0.15), OFIX: 44.33 (-0.42)
GNC Holdings: Retail a Bright Spot, Cash Balance Strong
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 12:00PM CDT
During 2015, GNC Holdings (GNC) generated operating cash flow of over $50.7 million, resulting in a 31.6% rise in free cash flow.
BAX: 44.94 (-0.07), GNC: 25.40 (+0.65), LMAT: 14.69 (+0.15), OFIX: 44.33 (-0.42)
Edwards Lifesciences' Solid Pipeline, Product Suite Impress
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 1:25PM CDT
Edwards Lifesciences (EW) ended 2015 on an outstanding note, with its fourth quarter numbers squarely beating the Zacks Consensus Estimate.
BAX: 44.94 (-0.07), LMAT: 14.69 (+0.15), EW: 98.04 (-0.53), OFIX: 44.33 (-0.42)
PAREXEL (PRXL): A Strong Buy on Solid Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 11:10AM CDT
On Apr 12, Zacks Investment Research raised PAREXEL International Corporation (PRXL) to a Zacks Rank #1 (Strong Buy).
PRXL: 59.45 (+0.07), LMAT: 14.69 (+0.15), PRAH: 42.91 (+0.43), OFIX: 44.33 (-0.42)
Phibro Animal Declines as FDA Moves to Revoke Mecadox
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 12:50PM CDT
A recent reexamination by the FDA has led the authority to question Phibro Animal Health Corporation's (PAHC) Mecadox drug's safety.
PAHC: 20.07 (+0.45), BAX: 44.94 (-0.07), LMAT: 14.69 (+0.15), OFIX: 44.33 (-0.42)
ResMed: Strong Cash Balance, Product Portfolio Drive Growth
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 1:50PM CDT
ResMed (RMD) currently has a strong cash balance, as evident from $269.5 million in cash flow from operations generated during the fiscal 2016 second quarter
BAX: 44.94 (-0.07), LMAT: 14.69 (+0.15), RMD: 62.33 (+0.55), OFIX: 44.33 (-0.42)
